Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Autor: Agathangelidis, A. Chatzidimitriou, A. Gemenetzi, K. Giudicelli, V. Karypidou, M. Plevova, K. Davis, Z. Yan, X.-J. Jeromin, S. Schneider, C. Pedersen, L.B. Tschumper, R.C. Sutton, L.-A. Baliakas, P. Scarfò, L. van Gastel, E.J. Armand, M. Tausch, E. Biderman, B. Baer, C. Bagnara, D. Navarro, A. Langlois de Septenville, A. Guido, V. Mitterbauer-Hohendanner, G. Dimovski, A. Brieghel, C. Lawless, S. Meggendorfer, M. Brazdilova, K. Ritgen, M. Facco, M. Tresoldi, C. Visentin, A. Patriarca, A. Catherwood, M. Bonello, L. Sudarikov, A. Vanura, K. Roumelioti, M. Skuhrova Francova, H. Moysiadis, T. Veronese, S. Giannopoulos, K. Mansouri, L. Karan-Djurasevic, T. Sandaltzopoulos, R. Bödör, C. Fais, F. Kater, A. Panovska, I. Rossi, D. Alshemmari, S. Panagiotidis, P. Costeas, P. Espinet, B. Antic, D. Foroni, L. Montillo, M. Trentin, L. Stavroyianni, N. Gaidano, G. Francia di Celle, P. Niemann, C. Campo, E. Anagnostopoulos, A. Pott, C. Fischer, K. Hallek, M. Oscier, D. Stilgenbauer, S. Haferlach, C. Jelinek, D. Chiorazzi, N. Pospisilova, S. Lefranc, M.-P. Kossida, S. Langerak, A.W. Belessi, C. Davi, F. Rosenquist, R. Ghia, P. Stamatopoulos, K. ERIC, the European Research Initiative on CLL

Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::02389fc31ced158666879616aa7abc06
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999928

Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact

Autor: Baliakas, P. Jeromin, S. Iskas, M. Puiggros, A. Plevova, K. Nguyen-Khac, F. Davis, Z. Matteo Rigolin, G. Visentin, A. Xochelli, A. Delgado, J. Baran-Marszak, F. Stalika, E. Abrisqueta, P. Durechova, K. Papaioannou, G. Eclache, V. DImou, M. Iliakis, T. Collado, R. Doubek, M. Calasanz, M.J. Ruiz-Xiville, N. Moreno, C. Jarosova, M. Leeksma, A.C. Panayiotidis, P. Podgornik, H. Cymbalista, F. Anagnostopoulos, A. Trentin, L. Stavroyianni, N. Davi, F. Ghia, P. Kater, A.P. Cuneo, A. Pospisilova, S. Espinet, B. Athanasiadou, A. Oscier, D. Haferlach, C. Stamatopoulos, K. on behalf of ERIC, the European Research Initiative on CLL

Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosomebanding analysis (CBA) may be relevant for treatment decision-making in chronic l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::55338e323279f41cfc8c60ef4964e431
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3000561

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Autor: Hehlmann, R., Lauseker, M., Baerlocher, G. M., Heim, D., Brümmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Saußele, S., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Balleisen, L., Goebeler, M. C., Hänel, M., Ho, A., Dengler, J., Falge, C., Pfirrmann, M., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Köhne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Krause, S., Berdel, W. E., Müller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, Roland, Wernli, M., Kolb, H. J., Schlegel, F., Schlag, R., de Wit, M., Trümper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Neubauer, A., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schäfer, E., Hochhaus, A., Hasford, J., Hossfeld, D. K., SAKK and the German CML Study Group, Nerl, C., Gratwohl, A.

Publikováno v: Leukemia : normal and malignant hemopoiesis 31, 2398-2406 (2017). doi:10.1038/leu.2017.253
Hehlmann, R; Lauseker, M; Saußele, S; Pfirrmann, M; Krause, S; Kolb, H J; Neubauer, A; Hossfeld, D K; Nerl, C; Gratwohl, A; Baerlocher, Gabriela M.; Heim, D; Brümmendorf, T H; Fabarius, A; Haferlach, C; Schlegelberger, B; Müller, M C; Jeromin, S; Proetel, U; Kohlbrenner, K; ... (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31(11), pp. 2398-2406. Nature Publishing Group 10.1038/leu.2017.253
Leukemia

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-fa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3844707224f159ade6c99ad4303c41b
http://edoc.mdc-berlin.de/16712/1/16712oa.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CEUS zur Muskelperfusionsdiagnostik: Ein neues Frühdiagnostikum des Kompartmentsyndroms?

Autor: Sellei, RM, Andruszkow, H, Jeromin, S, Zimmermann, F, Weber, CD, McCann, P, Hildebrand, F, Pape, HC

Publikováno v: Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2014); 20141028-20141031; Berlin; DOCWI52-264 /20141013/

Fragestellung: Die sichere Entscheidungsfindung für oder wider einer Fasziotomie im Fall eines akuten Kompartmentsyndroms ist bis heute, trotz klinischer Evaluation und apparativer Druckmessung, häufig eine Herausforderung. Die Machbarkeit einer Mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05c433b1fcbab0e65fd2375c72da304a